New PET imaging agent detects metastatic prostate cancer

Researchers at Memorial Sloan Kettering Cancer Center demonstrated that a new PET imaging agent can detect metastatic prostate cancer in regions that it has previously been difficult to spot. Results from the Phase 1 dose-escalation study of Zr-89-deferrioxamine-IAB2M were published in the December 2016 issue of The Journal of Nuclear Medicine.

With an estimated 1.1 million new cases and over 300,000 deaths annually from prostate cancer, it is the second most common cancer among men globally, according to the World Health Organization. Read more.

Tags: Cancer PET Prostate Research

About NMC  |  Products  |  Quote  |  News  |  Resources  |  Contact  |  Sitemap